Kindred Biosciences Executives
Kindred Biosciences employs about 63 people. The company is managed by 18 executives with a total tenure of roughly 111 years, averaging almost 6.0 years of service per executive, having 3.5 employees per reported executive. Analysis of Kindred Biosciences' management performance can provide insight into the firm performance.
| Richard Chin CEO President CEO, Director |
| Bartlomiej Weglewski Chairman Chairman of the Supervisory Board |
Kindred |
Kindred Biosciences Management Team Effectiveness
The company has Return on Asset of (23.11) % which means that on every $100 spent on assets, it lost $23.11. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (50.36) %, meaning that it generated no profit with money invested by stockholders. Kindred Biosciences' management efficiency ratios could be used to measure how well Kindred Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Kindred Biosciences Workforce Comparison
Kindred Biosciences is currently regarded as number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 20,976. Kindred Biosciences adds roughly 63.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Kindred Biosciences Notable Stakeholders
A Kindred Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kindred Biosciences often face trade-offs trying to please all of them. Kindred Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kindred Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard Chin | President CEO, Director | Profile | |
| Bartlomiej Weglewski | Chairman of the Supervisory Board | Profile | |
| Tomasz Jedrzejczak | Chairman of the Management Board | Profile | |
| Krystian Dejk | Chairman of the Management Board | Profile | |
| Stephen Sundlof | Senior Vice President - Regulatory Affairs | Profile | |
| Wendy Wee | CFO | Profile | |
| Denise Bevers | Co-Founder, COO and Secretary | Profile | |
| Herbert Montgomery | Independent Director | Profile | |
| Ernest Mario | Independent Director | Profile | |
| Raymond Townsend | Independent Director | Profile | |
| Ervin Veszpremi | Independent Director | Profile | |
| Hangjun Zhan | Chief Scientific Officer | Profile | |
| Slawomir Ryczkowski | Member of the Supervisory Board | Profile | |
| Hanna Smolinska | Member of the Supervisory Board | Profile | |
| Krzysztof Kochanowski | Member of the Supervisory Board | Profile | |
| Bozena Stromska | Member of the Supervisory Board | Profile | |
| Halina Kleba | Member of the Supervisory Board | Profile | |
| Lukasz Cieslak | Member of the Supervisory Board | Profile |
Kindred Biosciences Workforce Analysis
Traditionally, organizations such as Kindred Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kindred Biosciences within its industry.Kindred Biosciences Manpower Efficiency
Return on Kindred Biosciences Manpower
| Revenue Per Employee | 91.7K | |
| Revenue Per Executive | 321.1K | |
| Net Loss Per Employee | 665.9K | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 3.9M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Kindred Stock
If you are still planning to invest in Kindred Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kindred Biosciences' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |